Yabao Pharma In-licenses China Rights to Cancer Drug from Le Sun Pharma

Yabao Pharma partnered with Changzhou Le Sun Pharmaceuticals to co-develop Le Sun's leading molecule, a PLK/PI3K dual inhibitor that is in pre-clinical development for cancer. Yabao acquired exclusive China rights to LS-008 in China while Le Sun Pharma retained most of the exclusive rights in other markets. Founded in 2011, Le Sun Pharma develops oral therapies for cancer. More details.... Stock Symbol: (SHA: 600351) Share this with colleagues: // //